Survival Analysis

Early ctDNA Test Flags Which LS-SCLC Patients Benefit From Consolidation Immunotherapy

Post-induction ctDNA status predicted survival gains from checkpoint inhibitors in WCLC 2025 data, prompting calls for prospective validation.